- Home
- PTGX
as 11-14-2025 3:37pm EST
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | NEWARK |
| Market Cap: | 5.0B | IPO Year: | 2016 |
| Target Price: | $86.44 | AVG Volume (30 days): | 912.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.72 | EPS Growth: | -73.17 |
| 52 Week Low/High: | $33.31 - $93.25 | Next Earning Date: | 11-06-2025 |
| Revenue: | $209,217,000 | Revenue Growth: | -35.39% |
| Revenue Growth (this year): | -85.06% | Revenue Growth (next year): | 140.23% |
Stock Insider Trading Activity of Protagonist Therapeutics Inc. (PTGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Waddill William D. | PTGX | Director | Oct 10 '25 | Sell | $78.53 | 12,000 | $979,480.00 | 13,130 | |
| Waddill William D. | PTGX | Director | Sep 22 '25 | Sell | $64.25 | 4,000 | $257,000.00 | 13,130 |
Latest Protagonist Therapeutics Inc. News
PTGX Breaking Stock News: Dive into PTGX Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates
Associated Press Finance
8 days ago
Protagonist Therapeutics: Q3 Earnings Snapshot
ACCESS Newswire
8 days ago
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Simply Wall St.
10 days ago
Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting
Zacks
11 days ago
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?
Zacks
11 days ago
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates
ACCESS Newswire
11 days ago
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
Zacks
16 days ago
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?
Compare PTGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTGX Protagonist Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.